Clinical Trials Logo

Carcinoma in Situ clinical trials

View clinical trials related to Carcinoma in Situ.

Filter by:

NCT ID: NCT02631863 Completed - Clinical trials for Cervical Intraepithelial Neoplasia

Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)

Start date: March 22, 2016
Phase: Phase 2
Study type: Interventional

This trial will study the effectiveness of photodynamic therapy with aminolaevulinic acid for the treatment of patients with HPV+ low grade cervical intraepithelial neoplasia (LSIL;CIN1).

NCT ID: NCT02629510 Active, not recruiting - Cervical Cancer Clinical Trials

The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)

TACO
Start date: January 2015
Phase: Phase 4
Study type: Interventional

This study is aimed at identifying the efficacy of Tachosil® for prevention of hemorrhage in patients with cervical intraepithelial neoplasia or cervical cancer after undergoing a loop electrosurgical excisional procedure (LEEP). 1. Primary endpoint: Bleeding period within two weeks after surgery Frequency of additional treatment due to bleeding within two weeks after surgery 2. Secondary endpoint: Amount of bleeding within two weeks after surgery Infection frequency at external genitals, vagina and cervix within two weeks after surgery Change in life quality after surgery

NCT ID: NCT02620852 Recruiting - Breast Cancer Clinical Trials

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

WISDOM
Start date: August 31, 2016
Phase: N/A
Study type: Interventional

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mammograms and biopsies. With the current screening approach, half of the women who undergo annual screening for ten years will have at least one false positive biopsy. Potentially more important are cancer diagnoses for growths that might never come to clinical attention if left alone (called "overdiagnosis"). This can lead to unnecessary treatment. Even more concerning is evidence that up to 20% of breast cancers detected today may fall into the category of "overdiagnosis." This study compares annual screening with a risk-based breast cancer screening schedule, based upon each woman's personal risk of breast cancer. The investigators have designed the study to be inclusive of all, so that even women who might be nervous about being randomly assigned to receive a particular type of care (a procedure that is typical in clinical studies) will still be able to participate by choosing the type of care they receive. For participants in the risk-based screening arm, each woman will receive a personal risk assessment that includes her family and medical history, breast density measurement and tests for genes (mutations and variations) linked to the development of breast cancer. Women who have the highest personal risk of developing breast cancer will receive more frequent screening, while women with a lower personal risk would receive less frequent screening. No woman will be screened less than is recommended by the USPSTF breast cancer screening guidelines. If this study is successful, women will gain a realistic understanding of their personal risk of breast cancer as well as strategies to reduce their risk, and fewer women will suffer from the anxiety of false positive mammograms and unnecessary biopsies. The investigators believe this study has the potential to transform breast cancer screening in America.

NCT ID: NCT02617082 Recruiting - Breast Cancer Clinical Trials

Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery

Start date: October 2015
Phase: Phase 2
Study type: Observational [Patient Registry]

This study is designed to evaluate the feasibility and safety of partial breast irradiation for low risk DCIS after breast-conserving surgery.

NCT ID: NCT02615860 Completed - Clinical trials for Anal Intraepithelial Neoplasia (AIN) in HIV-infected Patients

Efficacy and Safety of TCA vs. ECA for the Treatment of AIN in HIV-positive Patients

TECAIN
Start date: November 2015
Phase: N/A
Study type: Interventional

Comparative evaluation of efficacy and safety of high-resolution anoscopy (HRA)-guided topical treatment (trichloroacetic acid, TCA) vs. surgical treatment (electrocautery, ECA) in HIV-positive patients for human papillomavirus (HPV)- induced AIN, an anal cancer precursor. The primary hypothesis is that cost-saving and simple TCA treatment is non-inferior to the current best option therapy with ECA. TCA treatment would also be possible in the normal setting of a doctor´s office without extensive specialization and without complex technical equipment.

NCT ID: NCT02605941 Recruiting - Cervical Cancer Clinical Trials

DNA Methylation Biomarkers for Cervical Cancer Screening

Start date: February 2014
Phase: N/A
Study type: Observational

The purpose of this prospective study is to evaluate whether DNA methylation can be applied in cervical cancer screening.

NCT ID: NCT02596243 Active, not recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

Start date: August 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)

NCT ID: NCT02596074 Completed - Clinical trials for Usual Type Vulval Intraepithelial Neoplasia (uVIN)

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Start date: November 2015
Phase: Phase 2
Study type: Interventional

To assess the pharmacodynamics, safety/tolerability and efficacy of topical Omiganan (CLS001) in patients with usual type vulvar intraepithelial neoplasia (uVIN).

NCT ID: NCT02587663 Completed - Clinical trials for Stage II Breast Cancer

Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI

Start date: November 20, 2005
Phase: N/A
Study type: Interventional

This clinical trial studies mammography and targeted ultrasound with or without whole-breast ultrasound or contrast-enhanced magnetic resonance imaging (MRI) in finding out the extent of disease before surgery in patients with newly diagnosed breast cancer. New diagnostic imaging procedures, such as whole-breast ultrasound or contrast-enhanced MRI, may help find out how far breast cancer has spread. It is not yet known whether mammography and targeted ultrasound are more effective with or without whole-breast ultrasound or contrast-enhanced MRI in finding out how far breast cancer has spread.

NCT ID: NCT02576262 Recruiting - Cervical Cancer Clinical Trials

HPV Integration Testing for Human Papillomavirus-Positive Women

Start date: September 2015
Phase: N/A
Study type: Observational

Papanicolaou (Pap) triage, with high specificity, has been recommended for primary Human papillomavirus (HPV) testing but is flawed by poor sensitivity and cytologist dependence. the investigators evaluated the potential role of HPV Integration detection in cervical exfoliated cells in HPV-positive women from a clinic-based population.